Padcev (enfortumab vedotin)

pCPA File Number: 21705

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adult patients with unresectable, locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy.

Sponsor/Manufacturer:

Seagen Canada Inc.

CADTH Project Number:

PC0251

pCPA Engagement Letter Issued:

2022-06-28

Negotiation Process Concluded:

2022-11-28